Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.
about
Antibiotic therapy for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in non surgical woundsTedizolid phosphate (sivextro): a second-generation oxazolidinone to treat acute bacterial skin and skin structure infectionsAdvances in antibiotic therapy in the critically illNew Is Old, and Old Is New: Recent Advances in Antibiotic-Based, Antibiotic-Free and Ethnomedical Treatments against Methicillin-Resistant Staphylococcus aureus Wound InfectionsWhat's new in multidrug-resistant pathogens in the ICU?New developments in the management of severe skin and deep skin structure infections - focus on tedizolidAntibiotics in the clinical pipeline at the end of 2015.Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.Tedizolid Phosphate: a Next-Generation Oxazolidinone.Safety profiles of old and new antimicrobials for the treatment of MRSA infections.Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.Avoidable antibiotic exposure for uncomplicated skin and soft tissue infections in the ambulatory care setting.Clinical characteristics and antibiotic utilization in pediatric patients hospitalized with acute bacterial skin and skin structure infection.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrugTedizolid population pharmacokinetics, exposure response, and target attainment.Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infections.Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.Tedizolid phosphate.Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolidNonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial functionAnalysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infectionsEarly response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH study.Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infectionsTreatment outcome measures for randomized controlled trials of antibiotic treatment for acute bacterial skin and skin structure infections in the emergency department settingSystematic Review and Meta-Analysis To Estimate Antibacterial Treatment Effect in Acute Bacterial Skin and Skin Structure Infection.Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA.Stability of Crushed Tedizolid Phosphate Tablets for Nasogastric Tube Administration.Sivextro (Tedizolid Phosphate) Approved for the Treatment of Adults with Acute Bacterial Skin and Skin-Structure Infections.Efficacy and Safety of AFN-1252, the First Staphylococcus-Specific Antibacterial Agent, in the Treatment of Acute Bacterial Skin and Skin Structure Infections, Including Those in Patients with Significant ComorbiditiesPipeline of Known Chemical Classes of Antibiotics.A Randomized Trial of Clindamycin Versus Trimethoprim-sulfamethoxazole for Uncomplicated Wound InfectionIn vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.Early Response in Cellulitis: A Prospective Study of Dynamics and Predictors.Impact of hospital variables on case mix index as a marker of disease severity.Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force.New antibiotics for bad bugs: where are we?Current treatment for nocardia infections.Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate.New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections.
P2860
Q24202424-7AAE797A-7E91-49BF-ACA7-3983F4EAC817Q24561509-E1E18BEA-D58C-4ABD-983B-87021D6F5FA7Q26749328-062D3E4B-D0CF-4F53-BE81-042545519A87Q26749376-A9F620FC-8EDF-4C94-B526-897A5DAB34E4Q28071346-A1B7CC11-0631-449C-A8AF-78EF2173596DQ28083116-5669457F-4448-44F1-B384-13E7381C259AQ30249262-AF6CCCC3-F0EE-4E38-B749-B535ADB4208FQ33417790-86EFC81F-8B6A-4E40-AA76-6E1915608463Q33420646-C59CD573-DBF0-416C-8206-EF8456966274Q33429168-3CF0B0E6-441D-477B-8CD9-285E795DC42AQ33438834-B759EBB6-80A3-47FD-932C-BA8D66D91379Q33821191-5D15A741-269D-461E-9936-E56CDC21F6E2Q34199990-07C3B532-B2A4-44A6-9746-B6D7BC8679DFQ34478074-90F96579-628D-43DB-BAC4-5F175E56A177Q34548251-C1F270CF-A551-43E5-AA82-99C2EEC99DC5Q34596353-3B95859B-B08E-4F49-B3B6-2442D2DFBB80Q34596497-D5112B8E-D383-4C6B-A52F-1C815E7E1456Q34596658-8C44544D-A6BC-4ECD-9E80-04F63839AA7BQ34612944-806D0764-E0EE-4558-9E4B-A6DCF4DB5CF1Q34658779-2BD20ABE-7C11-4645-A53F-93E60675F9E0Q34922189-DB5998CA-4464-4D3C-B13E-F5FE5335DAD3Q35105971-7703463C-7345-4D7A-87F2-9C30E806941DQ35155399-B97A0BA2-AE1D-4BE7-BB1F-32D07712E101Q35542330-A04C788E-0548-4E26-A564-4227CF63BD08Q35656230-C3D0F491-FF16-41A6-9932-18883B3DCB88Q35860102-DCB3802C-AC61-4F1D-B64D-B29E777AFC07Q36243256-41719DAF-F90B-4C56-8CD8-F96D1F367331Q36327804-8BA2FA3F-53DD-4C56-8EFF-04225E12EAF4Q36333768-5EFA9D2E-510B-40D6-BD82-E449EDBFD760Q36644729-99DDD6CF-E2F0-46F1-A863-C869C6609B0FQ36683409-CF6886AD-1896-49AF-8927-0C261BDE844AQ36948122-9A4AB641-F83C-4C9C-92FD-539DCA013612Q36969769-E1B96030-81EE-4DA4-AD61-D2DF03F95E63Q37284156-A925CBE6-4BDB-4D3D-870C-A7CFB9844F9CQ37597121-CE252E7F-DA24-493A-8853-043AE6778EC4Q37737061-0B3C63FB-C11F-4B8C-BF89-2129BB94BCA0Q38132217-450B1112-6EEA-4B54-BC84-74854B0ECDE9Q38149157-0783B463-338F-4031-8105-334B53B10D9FQ38171760-26F41FE7-E9CC-4D94-A962-93F3517568D5Q38179460-F8900160-0121-46F5-956F-A02A5C4C6D66
P2860
Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Tedizolid phosphate vs linezol ...... ESTABLISH-1 randomized trial.
@en
type
label
Tedizolid phosphate vs linezol ...... ESTABLISH-1 randomized trial.
@en
prefLabel
Tedizolid phosphate vs linezol ...... ESTABLISH-1 randomized trial.
@en
P2093
P356
P1476
Tedizolid phosphate vs linezol ...... ESTABLISH-1 randomized trial.
@en
P2093
Carisa De Anda
Edward Fang
Philippe Prokocimer
Purvi Mehra
P304
P356
10.1001/JAMA.2013.241
P407
P577
2013-02-01T00:00:00Z